Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

PD-L1 Expression in Triple-Negative Breast Cancer

Elizabeth A. Mittendorf, Anne V. Philips, Funda Meric‐Bernstam et al. · Cancer Immunology Research · 2014 · 1.4K citations · Full text

Medicine, Molecular Biology, Oncology +17

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

Biagio Ricciuti, Xinan Wang, Joao V. Alessi et al. · JAMA Oncology · 2022 · 384 citations · Full text

Medicine, Cancer Biology, Oncology +17

PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody

Gao‐Chao Lv, Xiaorong Sun, Ling Qiu et al. · Journal of Nuclear Medicine · 2019 · 176 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Peptide-Based ⁶⁸Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer

Ravindra A. De Silva, Dhiraj Kumar, Ala Lisok et al. · Molecular Pharmaceutics · 2018 · 144 citations · Full text

Medicine, Nuclear Medicine, Oncology +17